Evidence map›Paper›PMID 41267169›Full record

ArticleInflammatory bowel diseases2026

Mucosal B Cell Expansion and Maturation Contribute to Colitis Pathogenesis.

Ivan C N Fung, Pim J Koelink, Lieven G M Mulders, Iris Admiraal, Caroline Verseijden, Jan Verhoeff, Manon E Wildenberg, Yi Luo, Geert R D'Haens, Andrew Y F Li Yim and 1 more

Abstract read
In one paragraph

Article in Inflammatory bowel diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Ivan C N FungTytgat Institute for Liver and Intestinal Research, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0009-0008-5333-0915
Pim J KoelinkTytgat Institute for Liver and Intestinal Research, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-8403-3082
Lieven G M MuldersDepartment of Gastroenterology and Hepatology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-1001-1291
Iris AdmiraalTytgat Institute for Liver and Intestinal Research, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-3335-4924
Caroline VerseijdenTytgat Institute for Liver and Intestinal Research, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0009-0001-9284-5734
Jan VerhoeffTytgat Institute for Liver and Intestinal Research, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-0648-0642
Manon E WildenbergTytgat Institute for Liver and Intestinal Research, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-0671-818X
Yi LuoTranslational Medicine, Bristol Myers Squibb, Lawrenceville, NJ, United States.
Geert R D'HaensDepartment of Gastroenterology and Hepatology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-2784-4046
Andrew Y F Li YimTytgat Institute for Liver and Intestinal Research, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-0754-0953
Wouter J de JongeTytgat Institute for Liver and Intestinal Research, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-3241-1547

Funding

Bristol-Myers SquibbBristol-Myers Squibb. While Bristol-Myers SquibbJanssen Pharmaceutical Companies of Johnson & JohnsonJanssen Prevention Center of Janssen Vaccines & Prevention BV
6 · The paper itself

Abstract

backgroundUlcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing and remitting mucosal inflammation of the colon. While active UC mucosa is characterized by dysregulated B cell responses and increased B cell and IgG plasma cell populations, targeting CD20-expressing B cells in UC has proven ineffective.

methodsWe conducted an exploratory single-cell transcriptomic analysis of colonic biopsies obtained from UC patients with (n = 5) or without (n = 5) active inflammation, and non-UC controls (n = 4). To explore whether B cells contribute to colitis severity, we transferred various ratios of spleen-derived naive B cells with CD45RBhigh T cells into severe combined immune deficient mice to induce colitis.

resultsOur analysis identified a distinct subset of naive (MS4A1+CD27-IGHD+TCL1A+) B cells that are significantly enriched and present a more matured phenotype in inflamed compared to non-inflamed biopsies from UC patients. Cell-cell communication analysis indicated that naive B cells interacted predominantly with CD4+ T cell subsets. In the mice transfer colitis model, co-transfer of naive B cells at a ratio of 1-2 T and B cells, respectively, showed an increased maturation and activity, which led to exacerbation of colitis as measured by weight loss, increased colon density, and histological inflammation.

conclusionOur findings suggest that naive B cells expand in actively inflamed mucosa from UC patients and play a pathogenic role in experimental colitis.

Indexed as

B-LymphocytesColitisColitis, UlcerativeIntestinal MucosaAdultAnimalsCase-Control StudiesCD4-Positive T-LymphocytesColonDisease Models, AnimalFemaleHumansMaleMiceMice, SCIDMiddle AgedB cell maturation and expansionB cell pathologymice colitis transfer modelsingle-cell RNA-sequencingulcerative colitis

Identifiers

PMID41267169
PMCPMC12857420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.